Quality Controls in Ligand Binding Assays: Recommendations and Best Practices for Preparation, Qualification, Maintenance of Lot to Lot Consistency, and Prevention of Assay Drift.


Journal

The AAPS journal
ISSN: 1550-7416
Titre abrégé: AAPS J
Pays: United States
ID NLM: 101223209

Informations de publication

Date de publication:
11 07 2019
Historique:
received: 25 04 2019
accepted: 06 06 2019
entrez: 13 7 2019
pubmed: 13 7 2019
medline: 22 7 2020
Statut: epublish

Résumé

Quality controls (QCs) are the primary indices of assay performance and an important tool in assay lifecycle management. Inclusion of QCs in the testing process allows for the detection of system errors and ongoing assessment of the reliability of the assay. Changes in the performance of QCs are indicative of changes in the assay behavior caused by unintended alterations to reagents or to the operating conditions. The focus of this publication is management of QC life cycle. A consensus view of the ligand binding assay (LBA) community on the best practices for factors that are critical to QC life cycle management including QC preparation, qualification, and trending is presented here.

Identifiants

pubmed: 31297703
doi: 10.1208/s12248-019-0354-6
pii: 10.1208/s12248-019-0354-6
pmc: PMC6647453
doi:

Substances chimiques

Biomarkers 0
Indicators and Reagents 0
Ligands 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

89

Références

AAPS J. 2007 Apr 20;9(2):E117-22
pubmed: 17614353
Pharm Res. 2003 Nov;20(11):1885-900
pubmed: 14661937
Am J Clin Pathol. 1950 Nov;20(11):1059-66
pubmed: 14783086
J Pharm Biomed Anal. 2008 Dec 15;48(5):1267-81
pubmed: 18993008
AAPS J. 2015 Jul;17(4):939-47
pubmed: 25903932
AAPS J. 2017 Dec 27;20(1):22
pubmed: 29282611
Pharm Res. 2007 Oct;24(10):1962-73
pubmed: 17458684
JIMD Rep. 2018;38:89-95
pubmed: 28643276
Biochim Biophys Acta. 2016 Jan;1860(1 Pt B):315-24
pubmed: 26318015
AAPS J. 2014 Mar;16(2):221-5
pubmed: 24395373
N Engl J Med. 2012 Jun 28;366(26):2528; author reply 2528-9
pubmed: 22738111
Clin Lab Med. 2013 Mar;33(1):111-24
pubmed: 23331732

Auteurs

Mitra Azadeh (M)

Bioanalytical and Biomarker Development, Shire, Lexington, Massachusetts, USA. mitra.azadeh@takeda.com.

Perceval Sondag (P)

Pharmalex Inc, Flemington, New Jersey, USA.

Ying Wang (Y)

BioMedicine Design, Pfizer, Andover, Massachusetts, USA.

Maribeth Raines (M)

Laboratory Services at Pacific Biomarkers, Inc., Seattle, Washington, USA.

Jeffrey Sailstad (J)

Sailstad & Associates, Inc., Durham, North Carolina, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH